Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 16 | 2024 | 992 | 2.470 |
Why?
|
| Lupus Nephritis | 5 | 2021 | 102 | 1.020 |
Why?
|
| Antibodies, Antinuclear | 5 | 2021 | 183 | 0.870 |
Why?
|
| Complement C3 | 2 | 2020 | 21 | 0.810 |
Why?
|
| Complement Activation | 2 | 2020 | 27 | 0.800 |
Why?
|
| Complement C4 | 2 | 2020 | 16 | 0.690 |
Why?
|
| Patient Participation | 1 | 2020 | 56 | 0.620 |
Why?
|
| Decision Making | 1 | 2020 | 177 | 0.570 |
Why?
|
| Biomarkers | 7 | 2021 | 770 | 0.560 |
Why?
|
| Kidney | 2 | 2016 | 286 | 0.550 |
Why?
|
| Complement System Proteins | 1 | 2017 | 24 | 0.530 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 301 | 0.520 |
Why?
|
| Cytokines | 2 | 2024 | 448 | 0.490 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 70 | 0.490 |
Why?
|
| Fish Oils | 1 | 2015 | 12 | 0.470 |
Why?
|
| Fatigue | 1 | 2015 | 64 | 0.450 |
Why?
|
| Adult | 14 | 2024 | 7922 | 0.400 |
Why?
|
| B-Lymphocytes | 4 | 2024 | 285 | 0.400 |
Why?
|
| Middle Aged | 12 | 2024 | 7310 | 0.390 |
Why?
|
| Quality of Life | 1 | 2015 | 504 | 0.350 |
Why?
|
| Young Adult | 7 | 2020 | 2804 | 0.330 |
Why?
|
| Male | 14 | 2024 | 13772 | 0.320 |
Why?
|
| Female | 15 | 2024 | 15472 | 0.310 |
Why?
|
| Antimalarials | 2 | 2019 | 25 | 0.300 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 461 | 0.300 |
Why?
|
| Humans | 20 | 2024 | 28585 | 0.300 |
Why?
|
| Adolescent | 4 | 2020 | 3165 | 0.220 |
Why?
|
| Extracellular Traps | 1 | 2024 | 9 | 0.210 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 272 | 0.200 |
Why?
|
| Case-Control Studies | 3 | 2020 | 732 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 149 | 0.200 |
Why?
|
| Erythrocytes | 2 | 2020 | 88 | 0.190 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 166 | 0.190 |
Why?
|
| Flow Cytometry | 2 | 2020 | 291 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 216 | 0.180 |
Why?
|
| Calcineurin Inhibitors | 1 | 2021 | 5 | 0.180 |
Why?
|
| Cyclosporine | 1 | 2021 | 23 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 23 | 0.180 |
Why?
|
| Enterococcus | 1 | 2021 | 19 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 389 | 0.170 |
Why?
|
| Antibodies, Bacterial | 1 | 2021 | 103 | 0.170 |
Why?
|
| Altruism | 1 | 2020 | 8 | 0.160 |
Why?
|
| Tumor Necrosis Factors | 2 | 2017 | 15 | 0.160 |
Why?
|
| Intestines | 1 | 2021 | 118 | 0.160 |
Why?
|
| Culture | 1 | 2020 | 27 | 0.160 |
Why?
|
| Complement C4b | 1 | 2019 | 4 | 0.160 |
Why?
|
| Focus Groups | 1 | 2020 | 101 | 0.160 |
Why?
|
| Perception | 1 | 2020 | 90 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 75 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 135 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 210 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 8 | 0.150 |
Why?
|
| Biopsy | 2 | 2016 | 207 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2018 | 20 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 149 | 0.150 |
Why?
|
| Aged | 4 | 2024 | 5525 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 988 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2020 | 200 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 285 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2019 | 202 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 47 | 0.140 |
Why?
|
| African Americans | 1 | 2020 | 352 | 0.140 |
Why?
|
| Autoantibodies | 2 | 2019 | 479 | 0.140 |
Why?
|
| Cytokine TWEAK | 1 | 2017 | 2 | 0.130 |
Why?
|
| Angiostatins | 1 | 2017 | 2 | 0.130 |
Why?
|
| Lipocalin-2 | 1 | 2017 | 6 | 0.130 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2017 | 20 | 0.130 |
Why?
|
| Ferritins | 1 | 2017 | 27 | 0.130 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2017 | 37 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 47 | 0.130 |
Why?
|
| ADAM10 Protein | 1 | 2016 | 1 | 0.130 |
Why?
|
| ADAM17 Protein | 1 | 2016 | 13 | 0.130 |
Why?
|
| Oklahoma | 1 | 2020 | 1038 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 194 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 51 | 0.120 |
Why?
|
| Biological Factors | 1 | 2015 | 12 | 0.120 |
Why?
|
| Interleukin-13 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Single-Blind Method | 1 | 2015 | 46 | 0.120 |
Why?
|
| Interleukin-12 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 140 | 0.120 |
Why?
|
| DNA | 1 | 2017 | 375 | 0.120 |
Why?
|
| Resistin | 1 | 2015 | 4 | 0.120 |
Why?
|
| Adiponectin | 1 | 2015 | 29 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2015 | 39 | 0.110 |
Why?
|
| Leptin | 1 | 2015 | 67 | 0.110 |
Why?
|
| Proteomics | 1 | 2016 | 192 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 807 | 0.110 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 75 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2015 | 458 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2015 | 405 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2020 | 1455 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 97 | 0.100 |
Why?
|
| Mycophenolic Acid | 2 | 2024 | 18 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2015 | 265 | 0.100 |
Why?
|
| Disease Progression | 3 | 2019 | 475 | 0.090 |
Why?
|
| Risk Factors | 1 | 2016 | 2111 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2015 | 671 | 0.090 |
Why?
|
| Inflammation | 1 | 2015 | 642 | 0.090 |
Why?
|
| Creatinine | 2 | 2021 | 59 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 426 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2021 | 421 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2021 | 2402 | 0.070 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 21 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 80 | 0.050 |
Why?
|
| Chemokines | 1 | 2024 | 74 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 54 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 147 | 0.050 |
Why?
|
| Physical Examination | 1 | 2023 | 53 | 0.050 |
Why?
|
| Neutrophils | 1 | 2024 | 183 | 0.050 |
Why?
|
| Vaccination | 1 | 2024 | 192 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 196 | 0.040 |
Why?
|
| Phenotype | 1 | 2023 | 682 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 48 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 115 | 0.040 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2019 | 3 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 2019 | 28 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Proteinuria | 1 | 2019 | 14 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 226 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 74 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 302 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 265 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 480 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 734 | 0.030 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2016 | 7 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2016 | 5 | 0.030 |
Why?
|
| fas Receptor | 1 | 2016 | 19 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 782 | 0.030 |
Why?
|
| Sjogren's Syndrome | 1 | 2019 | 274 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 1272 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 82 | 0.030 |
Why?
|
| Transaminases | 1 | 2015 | 10 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 67 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 124 | 0.030 |
Why?
|
| Proteome | 1 | 2016 | 78 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 328 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 18 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 1600 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 515 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2045 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 257 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 417 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2021 | 2612 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 698 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 247 | 0.030 |
Why?
|
| Macrophages | 1 | 2016 | 302 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 862 | 0.030 |
Why?
|
| United States | 1 | 2018 | 2201 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 1602 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 10583 | 0.010 |
Why?
|